SEPN

Septerna, Inc. Common Stock
SEPN
Market cap $444M

9.97 USD

+0.13

1.32%

At close May 19, 4:00 PM EDT

Pre-market

10.14

+0.17

1.71%

1 day

1.32%

5 days

39.44%

1 month

69.85%

3 months

79.64%

6 months

-58.80%

Year to date

-53.30%

1 year

-53.41%

5 years

-53.41%

10 years

-53.41%

About: Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.

Employees: 75

Healthcare Biotechnology

0

Funds holding %

of 7,202 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

108% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 12

2.52% more ownership

Funds ownership: 99.38% [Q4 2024] → 101.91% (+2.52%) [Q1 2025]

5% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 19

0% more funds holding

Funds holding: 70 [Q4 2024] → 70 (+0) [Q1 2025]

20% less funds holding in top 10

Funds holding in top 10: 5 [Q4 2024] → 4 (-1) [Q1 2025]

65% less call options, than puts

Call options by funds: $157K | Put options by funds: $444K

74% less capital invested

Capital invested by funds: $1.01B [Q4 2024] → $262M (-$748M) [Q1 2025]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$18

81%

upside

Avg. target

$22

116%

upside

High target

$25

151%

upside

2 analyst ratings

1 positive

50%

1 neutral

50%

0 negative

0%

Cantor Fitzgerald Josh Schimmer	151%upside $25	Overweight Maintained	16 May 2025
Wells Fargo Derek Archila	81%upside $18	Equal-Weight Maintained	16 May 2025

See Analyst Rankings

Financial journalist opinion

Based on 11 articles about SEPN published over the past 30 days

Septerna: Novo's Investment In Incretin Program Intrigues - One For The Watchlist

Septerna's partnership with Novo Nordisk is a strong endorsement, but the $195m upfront is modest (by Big Pharma standards) and milestone payments are not guaranteed. The company's innovative GPCR platform and deep pipeline are promising, yet early clinical setbacks and fierce competition raise execution risks. Septerna's cash position is solid for now, but future clinical expenses may require additional funding, potentially diluting current shareholders.

Septerna: Novo's Investment In Incretin Program Intrigues - One For The Watchlist

Septerna: Deal With Novo Nordisk Is A Game Changer While It Still Trades Well Below Net Cash

Septerna's partnership with Novo Nordisk validates its GPCR drug discovery platform and injects $195 million in upfront cash, with potential for more than $2 billion in milestone payments. The stock trades below net cash even after the Novo deal, offering investors a rare opportunity to buy the pipeline and partnership essentially for free. NVO will cover R&D costs for four programs, extending SEPN's cash runway and reducing burn rate, while de-risking early-stage development.

Septerna: Deal With Novo Nordisk Is A Game Changer While It Still Trades Well Below Net Cash

Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results

Announced Global Collaboration with Novo Nordisk to Develop Oral Small Molecules for Metabolic Diseases with Over $2.2 Billion in Potential Milestone Payments

Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results

Zacks Investment Research

ETFs to Capitalize on the Novo Nordisk-Septerna Deal

Novo Nordisk announces a $2.2 billion deal with Septerna to tap the growing obesity treatment market.

ETFs to Capitalize on the Novo Nordisk-Septerna Deal

Zacks Investment Research

Septerna Stock Surges on Oral Obesity Drug Deal With Novo Nordisk

SEPN is entitled to receive around $2.2 billion from NVO under the new collaboration deal, which aims to develop oral pills for obesity and other diseases.

Septerna Stock Surges on Oral Obesity Drug Deal With Novo Nordisk

Proactive Investors

Septerna stock pops on partnership with Novo Nordisk to develop obesity therapies

Septerna (NASDAQ:SEPN) shares surged almost 50% after the announcement of an exclusive global collaboration and license deal with Novo Nordisk (NYSE:NVO) to develop oral small molecule medicines targeting obesity and other cardiometabolic diseases. The partnership brings together Septerna's expertise in G protein-coupled receptor (GPCR) drug discovery with Nono Nordisk's established obesity and metabolic disease therapies, which include the injectables Wegovy and Ozempic.

Septerna stock pops on partnership with Novo Nordisk to develop obesity therapies

Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs

Septerna Inc. SEPN and Novo Nordisk A/S NVO announced an exclusive global collaboration and license agreement on Wednesday.

Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs

Investors Business Daily

Novo Nordisk Inks A Major Obesity Deal, Sending Shares Of New Partner Septerna Skyrocketing

Novo Nordisk inked an obesity deal worth up to $2.2 billion on Wednesday, and sent shares of Septerna into the stratosphere.

Novo Nordisk Inks A Major Obesity Deal, Sending Shares Of New Partner Septerna Skyrocketing

Novo Nordisk and Septerna Collaborate on Oral Medicines for Obesity and Other Diseases

The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other cardiometabolic diseases.

Novo Nordisk and Septerna Collaborate on Oral Medicines for Obesity and Other Diseases

Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments

Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule medicines for obesity, type 2 diabetes and other cardio-metabolic diseases that could be worth up to $2.2 billion for Septerna, they said on Wednesday.

Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments

See News Rankings

Charts implemented using Lightweight Charts™